Symbols

BCRX

BioCryst Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

Bearish Abandoned Baby

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BCRX

Biocryst Pharmaceuticals, Inc.

A biotechn company that develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases

Industry

Biological Technology

Established Date

Listing Date

03/04/1994

Exchange

NASDAQ Stock Exchange

Full-time Employees

435

Fiscal Year Ends

12-31

Website

www.biocryst.com

Security Type

Common stock

Office address

4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703

Business

Introduction

BioCryst Pharmaceuticals, Inc., a Delaware corporation, was originally established in 1986. The company is a global biotechnology company dedicated to improving the lives of patients with hereditary angioedema and rare diseases. Leveraging its expertise in structure-guided drug design, the company aims to develop first-in-class or first-in-class oral small molecule and injectable protein therapies for rare diseases that are difficult to treat.

Company Financials

EPS

BCRX has released its 2025 Q4 earnings. EPS was reported at 1.12, versus the expected 0.05, beating expectations. The chart below visualizes how BCRX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BCRX has released its 2025 Q4 earnings report, with revenue of 406.56M, reflecting a YoY change of 209.09%, and net profit of 245.84M, showing a YoY change of 1017.50%. The Sankey diagram below clearly presents BCRX's revenue sources and cost distribution.